Observational studyFrontiers in immunology2026
99mTc-FAPI-YQ3 SPECT/CT for characterizing FAPI uptake phenotypes and metabolic-stromal heterogeneity in advanced differentiated thyroid carcinoma: a prospective single-center imaging-radiomics study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Advanced and metastatic differentiated thyroid carcinoma (DTC), particularly radioactive iodine (RAI)-refractory disease, is characterized by spatially heterogeneous tumor biology and limited therapeutic options. Fibroblast activation protein inhibitor (FAPI)-targeted imaging may provide noninvasive imaging correlates of stromal-related tumor phenotypes; however, tracer uptake should not be interpreted as direct tissue proof of FAP expression without immunohistochemical or multi-omics validation. This exploratory study evaluated 99mTc-FAPI-YQ3 SPECT/CT for characterizing FAPI uptake phenotypes and metabolic-stromal imaging heterogeneity in advanced DTC. Methods: A quinolone-derived FAPI pharmacophore was designed using scaffold-hopping and conformational-constraint strategies and radiolabeled with 99mTc. From June 2024 to February 2025, patients with pathologically confirmed DTC and locally advanced, recurrent, nodal metastatic, or distant metastatic disease were prospectively enrolled in this single-center observational study. No formal sample-size calculation was performed because the study was designed as an exploratory first clinical imaging-radiomics analysis. All patients underwent whole-body 99mTc-FAPI-YQ3 SPECT/CT and 18F-FDG PET/CT within 1 week. Lesion detection, biodistribution, tumor-to-background ratio (TBR), dual-tracer concordance, and exploratory radiomics classification of FAPI uptake phenotypes were analyzed. Results: Seventeen patients with 103 lesions were included. The mean TBR of 99mTc-FAPI-YQ3 was 6.8 +/- 2.3, and the mean lesion diameter was 2.69 +/- 1.35 cm. Dual-tracer phenotypes included concordant FDG-positive/FAPI-positive lesions (54/103, 52.4%), FDG-positive/FAPI-negative lesions (44/103, 42.7%), and FDG-negative/FAPI-positive lesions (5/103, 4.9%); no FDG-negative/FAPI-negative lesion was observed. Overall crude concordance was 52.4%, Cohen kappa was -0.0955 (P = 0.0477), and the positive-class Jaccard index was 0.524. 99mTc-FAPI-YQ3 showed high detection rates for thyroid-bed lesions (19/21) and bone lesions (7/8), moderate detection of lymph-node lesions (18/29), and limited detection of pulmonary lesions (10/40). In the exploratory lesion-level radiomics analysis, the logistic-regression model showed AUC values of 0.951 in the training set, 0.927 in the validation set, and 0.874 in five-fold cross-validation. Conclusions: 99mTc-FAPI-YQ3 SPECT/CT appears to be a feasible and accessible approach for evaluating FAPI uptake phenotypes in advanced DTC. Dual FDG-FAPI imaging provides preliminary evidence of metabolic-stromal imaging heterogeneity, but the findings should be interpreted as imaging phenotypes rather than validated tissue-based FAP expression. Further prospective studies with histopathologic, immunohistochemical, multi-omics, and patient-level validation are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.